July 24 (Reuters) - Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.
The U.S. biotechnology company's net profit rose to $597.8 million, or 72 cents per share, in the second quarter ended June 30, from $478.1 million, or 56 cents per share, a year earlier.
Excluding special items, it earned 90 cents per share.
Total revenue rose 17 percent to $1.87 billion.
Sales of multiple myeloma treatment Revlimid rose 15 percent to $1.21 billion. (Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)